500 Class 02 (Recording)

https://thomaselove.github.io/500-2024/

2025-01-23

Agenda for Recorded Lecture

- STROBE checklist (items 13-21)
- The Hormone Replacement Therapy Story
 - Can Selection Bias Explain the Story?
- Tools for Assessing Causal Effects
 - Subclassification and Cochran's Example
 - Using Matched Sets to Adjust for Overt Bias
- Defining and Motivating the Propensity Score
- Matching using the Propensity Score: The Key Ideas
 - Some Foundations
 - How the PS is used in 1:1 matching

Section 1

The STROBE checklist

STROBE checklist on Results

- Participants
- Descriptive Data
- Outcome Data
- Main Results (unadjusted and adjusted estimates)
- Other Analyses (subgroups, etc.)

STROBE checklist on Discussion

- Key Results (refer to Study Objectives)
- Limitations (including sources of potential bias)
- Interpretation (a cautious interpretation see next slide for discussion of causation vs. correlation)
- Generalizability (external validity)

McGowan blog post and Bradford Hill (1965)

Causation or Association?

- Strength of effect
- Consistency (reliability and replicability)
- Specificity
- Temporality
- Biological gradient (dose effect, essentially)
- Plausibility
- Coherence (with what is known in the field)
- Experiment (implement a counterfactual)
- Analogy (similar effect from similar exposure?)

Section 2

The Hormone Replacement Therapy Story

Testing out Cause and Effect: Comparing Potential Outcomes

- The causal effect of a treatment is based on a comparison of two potential outcomes.
 - Outcome patient would have if treated.
 - Outcome patient would have if untreated.
- Causal effect = Treated Untreated difference (or ratio, or whatever)

The key problem is that we only get to observe **one** of these outcomes.


Hormone Replacement Therapy and Dementia

1998 Meta-Analysis from Yaffe et al.¹

- Estrogen associated with a 29% decreased risk of dementia
- Promising results for Alzheimer's disease (see next slide)

¹Yaffe K Sawaya G Lieberburg I Grady D Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA 1998 Mar 4;279(9):688-95. https://pubmed.ncbi.nlm.nih.gov/9496988/

1998 Meta-Analysis: Estrogen & Alzheimer's



Hormone Replacement Therapy and Dementia

• Burkman et al. 2001: "Estrogen and HRT users have ... a 20% to 60% reduction in the risk of Alzheimer's disease."²

BUT

- These studies discussed in the 1990s are, for the most part,
 - small in size
 - short in duration
 - non-randomized,
 - and uncontrolled.
- The largest and most methodologically sound observational study (Barret-Connor et al. 1993³) of the effect of estrogen use on cognition in non-demented women showed no benefit.

²Burkman RT Collins JA Greene RA Current perspectives on benefits and risks of hormone replacement therapy. Amer J of Obstetrics and Gynecology 2001 185 (2): S13-S23. https://pubmed.ncbi.nlm.nih.gov/11521117/

³Barrett-Connor E Estrogen and estrogen-progestogen replacement: therapy and cardiovascular diseases. Am J Med 1993 Nov 30;95(5A):40S-43S. https://pubmed.ncbi.nlm.nih.gov/8256794/

Hormone Replacement Therapy and Dementia

- Burkman et al. 2001: "Estrogen and HRT users have ... a 20% to 60% reduction in the risk of Alzheimer's disease."
- Craig et al. 2005: "Estrogen with or without progestin, given to women 65 years and older ... substantially increases the risk of dementia of any cause and cognitive decline."⁴

⁴Craig Michael C Maki Pauline M Murphy Declan G M The Women's Health Initiative Memory Study: findings and implications for treatment. Lancet Neurol 2005 Mar; 4(3): 190-4. https://pubmed.ncbi.nlm.nih.gov/15721829/

Cache County Memory Study

Zandi et al. 2002: Prospective study of incident dementia⁵


- This was a prospective study of incident dementia among 1357 men and 1889 women residing in a single county in Utah. Patients were first assessed in 1995-97, with follow-up 3 years later.
- Adjustments in models included terms for age and age squared, years of education, and presence of 1 or 2 APOE $\epsilon4$ alleles, and interactions.

Figure on next slide...

 $^{^5} Zandi$ Peter P Anthony James M Hayden Kathleen M et al. 2002 Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study. Neurology 2002 Sep 24;59(6):880-6. https://pubmed.ncbi.nlm.nih.gov/12297571/

Cache County Memory Study

Figure 2. Estimated Discrete Annual Hazard of Alzheimer Disease for Men and Women by Age, and by Duration of Hormone Replacement Therapy Use for Women



Both figures indicate risks estimated for an individual with the mean value of 13 years of education and no €4 alleles at APOE. A, The curves depict the annual hazards predicted by fitting the base model including an age-by-sex interaction term. The annual hazard for Alzheimen disease (AD) appears similar for men and women before 80 years of age but diverges rapidly afterward with an excess risk found in women. B, The curves depict the annual hazards predicted by fitting model 7 of Table 3 to the women with available hormone replacement therapy (HRT) exposure information and, in filled circles, the corresponding annual hazards for men after omitting the terms for HRT. There were 35 instances of incident AD among 1357 men. Ordinate values for women differ slightly from those in panel A due to omission of women lacking HRT exposure information, several of whom experienced incident dementia.

Conclusions from Cache County

- Women using HRT had a reduced risk of AD compared with non-HRT users (adjusted HR is 0.59).
- Risk varied with duration of HRT use, so that a woman's sex-specific increase in risk disappeared entirely with more than 10 years of treatment.
- Conclusions: Prior HRT use is associated with reduced risk of AD, but there is no apparent benefit with current HRT use unless such use has exceeded 10 years.

WHIMS (Women's Health Initiative Memory Study)

Randomized, controlled trial, reported by Shumaker et al. (2003, 2004) and by Espeland (2004) and more⁶

- 4,352 post-menopausal women age 65 or more
- Estrogen + Progestin HRT
 - increased risk (hazard ratio 2.05) for probable dementia
 - treating 434 women age 65+ with combination HRT would cause one new dementia case.
 - No significant impact on mild cognitive impairment

 $^{^6} See\ Shumaker\ SA\ et\ al.\ JAMA\ 2003\ https://pubmed.ncbi.nlm.nih.gov/12771112/and\ Shumaker\ SA\ et\ al.\ JAMA\ 2004\ https://pubmed.ncbi.nlm.nih.gov/15213206/and\ Espeland\ MA\ et\ al.\ JAMA\ 2004\ https://pubmed.ncbi.nlm.nih.gov/15213207/.$

WHIMS Baseline Comparisons

No significant baseline differences between the two arms of the trial in

- Age, Education,
- Smoking, Diabetes, Prior HRT or Aspirin use,
- or 3MSE score.

Significant differences (comparing E & P to placebo) in

- History of Stroke (1.0% vs. 1.9),
- Statin use (12.0 vs. 9.8), and
- Adherence (E & P less than Placebo)

• Stampfer et al 1985 [Nurses' Health Study] ... "estrogen reduces the risk of severe CHD."

- Stampfer et al 1985 [Nurses' Health Study] ... "estrogen reduces the risk of severe CHD."
- Col et al 1997 (JAMA) ... "HRT should increase life expectancy for nearly all postmenopausal women"

- Stampfer et al 1985 [Nurses' Health Study] ... "estrogen reduces the risk of severe CHD."
- Col et al 1997 (JAMA) ... "HRT should increase life expectancy for nearly all postmenopausal women"
- WHI trial 2002 (JAMA) ... "(HRT) should not be initiated or continued for primary prevention of coronary heart disease."

- Stampfer et al 1985 [Nurses' Health Study] ... "estrogen reduces the risk of severe CHD."
- Col et al 1997 (JAMA) ... "HRT should increase life expectancy for nearly all postmenopausal women"
- WHI trial 2002 (JAMA) ... "(HRT) should not be initiated or continued for primary prevention of coronary heart disease."
- Full references / PubMed links for these pieces as well as the 1991 NHS ten-year follow-up are available on the Class 02 README.

Selection Bias?

Comparing NHS (OS) to WHI (RCT)

- Healthy User Effect
 - Women with healthy behaviors may select to use postmenopausal hormones. (prevention bias)
- In the NHS,
 - HRT users tended to have better CV risk profiles
 - HRT users were generally better educated
 - Perhaps women taking HRT / ERT were "compliant" and such people have lower CHD risk.
 - HRT users have more contact with physicians, and are perhaps more health conscious, generally.

So... How Can We Avoid Being Misled?

- What differentiates an observational study from a randomized controlled trial?
 - One key element: potential for selection bias.
- What is selection bias, and why should I care about it?
 - Baseline characteristics of comparison groups are different in ways that affect the outcome.
 - We often split this into **overt** bias we observe in our measures
 - As compared to hidden bias across measures we didn't think to observe.
- What can be done to deal with selection bias in observational studies?
 - Propensity score methods for overt bias.
 - Sensitivity analyses to deal with hidden bias.

Benson and Hartz 2000

A Comparison of Observational Studies and Randomized, Controlled Trials For many years it has been claimed that observational studies find stronger treatment effects than randomized, controlled trials.

In only 2 of the 19 analyses of treatment effects did the combined magnitude of the effect in observational studies lie outside the 95% CI for the combined magnitude in the RCTs.

We found little evidence that estimates ... in observational studies reported after 1984 are ... qualitatively different from those obtained in RCTs.

Section 3

Tools for Assessing Causal Effects

Assessing the Causal Effect of an Exposure on an Outcome

Objective: Draw causal inferences between [use of exposure vs. non-use] and outcome

- Standard Approach: Risk Adjustment
- Problem: Selection Bias (exposed people are different from unexposed people at baseline, in ways that affect the outcome)
- Idea: Compare exposed to unexposed subjects that looked similar (had similar propensity for exposure) prior to the exposure decision

Overt, but no **Hidden** Bias Model

Two units with the same value of the covariates \mathbf{x} have the same probability π of receiving the exposure.

- An observational study is **free of hidden bias** if the unknown π_j s are known to depend only on the observed covariates x_j .
- Sometimes this is referred to as "randomization based on covariates"

How can we adjust for overt bias?

Simplest approach: stratify on the covariates \mathbf{x}

- Exact stratification two units are in the same stratum only if they have the same value of x.
- If there is no hidden bias and we stratify exactly, then all units in the same stratum have the same probability of treatment, so we can use methods appropriate for a randomized experiment.

A Simple Survival Comparison

Status at 30 days	Alive	Dead	Pr(Alive)
Without Exposure	80	120	0.40
With Exposure	130	70	0.65

- Without Exposure (perhaps as estimated by historical records) only 40% of subjects survived.
- With Exposure, we see a "clinically meaningful" improvement (65% of subjects survived.)
- p value from Fisher's exact test is < 0.001.

But was this a randomized trial, or an observational study?

Simple Survival Comparison

Suppose in addition to

- our outcome (Alive or Dead at 30 days)
- and exposure status,

we also had a **covariate**, say, sex, available for each subject. Suppose 200 of the subjects in the study are Male, and 200 are Female.

Suppose also that sex might be related to the outcome.

 Can we adjust for sex's effect in assessing the impact of our exposure on that same outcome? How?

Stratification in our Survival Comparison

ALL PATIENTS	Alive	Dead	Pr(Alive)
Without Exposure	80	120	0.40
With Exposure	130	70	0.65

Now, 200 of these subjects are Male, and 200 are Female.

Survival Comparison among Male Subjects

MALE	Alive	Dead	Pr(Alive)
Without Exposure	40	60	0.40
With Exposure	40	60	0.40

No difference between the exposed and unexposed group in terms of survival, among males. Is that also the story for our female subjects?

Survival Comparison among Female Subjects

MALE	Alive	Dead	Pr(Alive)
Without Exposure	40	60	0.40
With Exposure	40	60	0.40

FEMALE	Alive	Dead	Pr(Alive)
Without Exposure	40	60	0.40
With Exposure	90	10	0.90

Stratification allows comparison adjusting for sex.

Section 4

Cochran's Smoking Example

Cochran's Smoking Example

Reference: Cochran WG 1968 The Effectiveness of Adjustment by Subclassification in Removing Bias in Observational Studies *Biometrics* 24, 205-213. (available on our Sources page)

Outcome: mortality rates of US male [1] cigarette smokers, [2] cigar/pipe smokers and [3] non-smokers

US Death Rates per 1,000 person-years

Smoking Group	Unadjusted Death Rate
Non-Smokers	20.2
Cigarettes only	20.5
Cigars, pipes	35.5

Cochran's Smoking Example

Outcome: mortality rates of US male [1] cigarette smokers, [2] cigar/pipe smokers and [3] non-smokers

Let's look at an important covariate - any suggestions?

Cochran: US Death Rates per 1000 person-years

Smoking Group	Mean Age in Years	Unadjusted Death Rate
Non-Smokers	54.9	20.2
Cigarettes only	50.5	20.5
Cigars, pipes	65.9	35.5

Now, how could we adjust for the impact of age on our estimates of the death rate?

Subclassification on Age (3 subclasses)

Divide the subjects into 3 subclasses on the basis of age (low, middle, high)

- Calculate "low age" mortality rate in each smoking group
- Then calculate "middle age" and finally "high age" mortality rate in each smoking group
- Within the "non-smokers" combine the "low", "middle" and "high" mortality rate estimates by weighting according to the population proportions of "low", "middle" and "high" age.
- Repeat to obtain estimates for "cigarettes only" and "cigars, pipes"

Cochran: US Death Rates per 1000 person-years

Smoking Group	Mean Age	Unadjusted Death Rate	Adjusted for Age
Non- Smokers	54.9	20.2	20.3
Cigarettes only	50.5	20.5	28.3
Cigars, pipes	65.9	35.5	21.2

Cochran's Smoking Example

Outcome: mortality rates of US male [1] cigarette smokers, [2] cigar/pipe smokers and [3] non-smokers

- Subclassification on the covariate age
- Key Finding: Five subclasses are often sufficient to remove over 90% of the bias due to the subclassifying variable or covariate.
 - Even as few as 2 or 3 subclasses can have a big impact.

Why can't we always just do direct adjustment like this for covariates?

- Because we don't (typically) have only one covariate.
- As the number of covariates increases, the number of subclasses grows exponentially
 - ullet 2 categories for each of p covariates yields 2^p subclasses.
- ullet Also, if p is large, some subclasses will contain no units, or will contain only exposed or unexposed units but not both.

A solution? Propensity scores.

Aspirin Use and Mortality (Gum 2001)

6174 consecutive adults at CCF undergoing stress echocardiography for evaluation of known or suspected coronary disease⁷

- 2310 (37%) were taking aspirin (treatment).
- Main Outcome: all-cause mortality
 - Median follow-up: 3.1 years
- Univariate Analysis: 4.5% of aspirin patients died, and 4.5% of non-aspirin patients died.
 - Unadjusted Hazard Ratio: 1.08 (0.85, 1.39)

⁷Gum PA et al. Aspirin Use and All-Cause Mortality among Patients being Evaluated for Known or Suspected Coronary Artery Disease JAMA 2001 286(10): 1187-1194. See our sources page.

Matching on the Covariates, X

- We can create a **matched sample**, where we match treated subjects to control subjects, on the basis of their covariates.
 - Simplest is exact matching but this can pose problems unless we have few covariates to deal with, with very limited possible values.
 - Often exact stratification or matching is impossible, but when it is, things go smoothly.

What's the difference between Aspirin Users and the other patients?

Variable Aspirin Users No Aspirir			
	Variable	Aspirin Users	No Aspirin
Age, Mean (SD) 62 (11) 56 (12)	Age, Mean (SD)	62 (11)	3,864 56 (12) 56.1

Might it be reasonable to match up patients who are the same gender and similar in age? Or to stratify into groups by age and gender?

What's the difference between Aspirin Users and the other patients?

Variable	Aspirin Users	No Aspirin
Patients	2,310	3,864
Age, Mean (SD)	62 (11)	56 (12)
Male, %	77.0	56.1
Prior CAD, %	69.7	20.1
Beta Blocker, %	35.1	14.2

But now what do we do?

- How can we match on Age and Gender and history of CAD and beta-blocker prescription?
- Or (if that's not hard enough) how about the complete set of 31 covariates?

Using Matched Sets or Strata to Adjust for Overt Selection Bias

- Observe a set of p covariates, collected in X
- Even if each covariate is binary, there are 2^p possible values of X
 - Many subjects are likely to have unique values of X.
- \bullet Realistic Goal: compare treated and control groups with similar distributions of $\boldsymbol{X},$ even if matched individuals have differing values of \boldsymbol{X}

Key tool for doing this well: propensity score

What Do We Want to Know about a Clinical or Health System Intervention⁸?

- Response: Can we estimate the impact of the intervention? Can we estimate costs and benefits?
- Predictors: Can we "mine" for attributes that help predict response to the intervention?
- Evaluation: Can we fairly estimate the average health impact of our intervention?
- Target Evaluation: Can we identify likely responders? Subgroup analyses?

⁸from a marketing list at www.anabus.com

The Data You Wish You Had

Health if exposed	if unexposed
12	8
7	4
7	3
12	9
	12 7 7

ALL potential outcomes available!

The Data You Wish You Had

Subject	Health if exposed	if unexposed	Exposure Effect
Α	12	8	4
В	7	4	3
C	7	3	4
D	12	9	3

Wouldn't this be great!

Grim Reality


Subject	Health if exposed	if unexposed	Exposure Effect
A	12	?	?
В	7	?	?
C	?	3	?
D	?	9	?


Causal inference is a missing data problem.

How should we fill in those question marks?

Section 5

Matching and Causal Effects









Add baseline characteristics

1

3


В


4


6


D


No Exposure























Section 6

The Propensity Score

The Propensity Score

Definition: The conditional probability that a subject receives an exposure given the values of their vector of covariates.

PS = Pr(exposed | covariates)

Reduces the baseline information to a single, composite summary of the covariates, between 0 and 1.

- Of course, we know whether a subject in fact either receives or doesn't receive the exposure.
- But we will estimate this probability for each subject as a convenient way of expressing the impact of covariate information on the exposure assignment decision, as a scalar value between 0 and 1.

Estimating the Propensity Score

The most common approach is to estimate a Logistic Regression Model:


- Y = Exposure Group
 - 1 = exposed, 0 = unexposed
- Predictors are the observed covariates


Use anything related to exposure decisions that can be collected prior to exposure assignment.

Propensity Scores = Predicted Pr(exposure) for each subject, i.e. the **fitted values**

Why Estimate Pr(subject was "exposed")?


- Using Pr(subject would have been exposed), we create a quasi-randomized experiment.
- If we have two subjects, one treated and one control, with the same propensity score, we can imagine that these two subjects were randomly assigned to each group - just as if we were doing an experiment!
- Except that here we can't assume that we control for anything that we didn't measure.







No Exposure




Add PROPENSITY to be Exposed




.62 .74 .59 .81 A B C D

Which pairs should we compare?

Causal Analysis



Causal Analysis



Grim Reality

Subject	Health if exposed	Health if unexposed	Exposure Effect
A	12	?	?
В	7	?	?
C	?	3	?
D	?	9	?

Improving Grim Reality

Propensity for Exposure	Health if exposed	if unexposed
0.80	12	?
0.50	7	?
0.51	?	3
0.79	?	9
	0.80 0.50 0.51	0.50 7 0.51 ?

- Can we use the propensity score to guide our matching approach?
- Can we plug in resulting estimates for our question marks?

Propensity Score Matching yields a new Database

Subject	PS	Health if exposed	if unexposed	Exposure Effect
A	0.80	12	[9]	[3]
В	0.50	7	[3]	[4]
C	0.51	[7]	3	[4]
D	0.79	[12]	9	[3]

Now, we can estimate the **impact of the exposure** on each matched patient.

How Do We Use the Propensity Score?

- Start with a sample where the exposed subjects don't look very much like the unexposed subjects.
- Adjust the sample (in some manner) to make the distributions of exposed and unexposed subjects look more similar prior to exposure.
- This will let us attribute the differences we see in outcomes between these adjusted samples more easily to the exposure's causal effect, and not so much to the original differences between the groups.
- To do this, we estimate the propensity score: the probability of receiving the exposure for each subject given their covariate values.
- Then, we use the propensity score in one of the ways listed on the next slide to fuel our estimates of causal effects.

Methods for Using Propensity Scores


- Subclassification / Stratification on the Propensity Score
- Direct (Regression) Adjustment using the Propensity Score
- Matching using the Propensity Score
- Weighting using the Propensity Score
- Combining Approaches for More Robust Estimation

I'll demonstrate R code for all of these ideas soon.

Section 7

Using the Propensity Score

When is the propensity score useful?



from Emily Riederer

Estimating the Propensity Score

The most common approach is to estimate a Logistic Regression Model:

- Y = Exposure Group
 - 1 = exposed, 0 = unexposed
- Predictors are the observed covariates

Use anything related to exposure decisions that can be collected prior to exposure assignment.


Propensity Scores = Predicted Pr(exposure) for each subject, i.e. the **fitted values**

Why Estimate Pr(subject was "exposed")?


- Using Pr(subject would have been exposed), we create a quasi-randomized experiment.
- If we have two subjects, one treated and one control, with the same propensity score, we can imagine that these two subjects were randomly assigned to each group - just as if we were doing an experiment!
- Except that here we can't assume that we control for anything that we didn't measure.

A Simple Observational Study


Simple Observational Study



Apply the Exposure



To estimate causal effects, we need the baseline covariates to be in balance...



Model Without the Propensity Score

Outcome = $\beta_0 + \beta_1$ *Exposure,


for pool of 75 subjects We interpret $\[\mathbf{6}_{1} \]$ as the exposure's effect.




Subjects vary, within exposure groups...


Exposed (n = 25)

\(\times \t





Actually, they vary quite a bit ...






Actually, they vary even more than that







Characterize by propensity to receive the exposure...









Are baseline characteristics in balance?



Comparing Exposure Groups Fairly?





Model Without the Propensity Score

Outcome = $\beta_0 + \beta_1$ *Exposure, for pool of 75 subjects We interpret β_1 as the exposure's effect.



Could include covariates, as well...

Outcome = $\beta_0 + \beta_1$ *Exposure + β_j *Covariate_j, for pool of 75 subjects

Still interpret **B**₁ as the exposure's effect, after covariate adjustment.



Section 8

Propensity Score Matching

Exposed Pool

 $\triangle \triangle$

 $\Diamond \Diamond \Diamond$

0000000

~~~~~~~


"Not Exposed" Pool


 $\diamond\diamond\diamond\diamond\diamond\diamond\diamond\diamond\diamond\diamond\diamond$ 

\*\*\*

00000000

~~~~~





Exposed Pool "Not Exposed" Pool











Form a matched pair

We're matching without replacement.

^^^^











Exposed Pool

AA

Find a good match among the subjects not exposed.

The pool of the pool

Exposed Pool












Keep matching, until we can find no more acceptable matches



"Not Exposed" Pool











Exposed Pool (unmatched)




Matched Set (24 pairs)



"Not Exposed" Pool (unmatched)



Matched Set (24 pairs)



Within each matched pair, compare outcome in exposed subject to outcome in "not exposed" subject.

Estimated outcome effect Within a specific pair j is estimated by δ_{i}

Matched Set (24 pairs)



Within each matched pair, compare outcome in exposed subject to outcome in "not exposed" subject.

Use standard methods for matched samples (e.g., paired t tests) to estimate the causal effect of the exposure on the outcome based on the δ estimates from the pairs

How Do We Use the Propensity Score?

- Start with a sample where the exposed subjects don't look very much like the unexposed subjects.
- Adjust the sample (in some manner) to make the distributions of exposed and unexposed subjects look more similar prior to exposure.
- This will let us attribute the differences we see in outcomes between these adjusted samples more easily to the exposure's causal effect, and not so much to the original differences between the groups.
- To do this, we estimate the propensity score: the probability of receiving the exposure for each subject given their covariate values.
- Then, we use the propensity score in one of the ways listed on the next slide to fuel our estimates of causal effects.

Methods for Using Propensity Scores

- Subclassification / Stratification on the Propensity Score
- Direct (Regression) Adjustment using the Propensity Score
- Matching using the Propensity Score
- Weighting using the Propensity Score
- Combining Approaches for More Robust Estimation

I'll demonstrate R code for all of these ideas soon, but first, we'll discuss them without the hassle of trying to get the machine to run them for us.

What Propensity Scores Can and Cannot Do

- If we match exposed subjects to controls with similar propensity scores, we can (sort of) behave as if they had been randomly assigned to exposures.
- But if our propensity model misses an important reason why subjects are selected to an exposure, we'll be in trouble, and we'll never know it.

Section 9

Finishing Up

Agenda for Class 2 Zoom Call

Thursday 2025-01-23 from 10 to 11 AM. Zoom details in your email and on Canvas.

- Welcome to 500 Survey
- Lab 0 and how things are going so far
- Abramson Chapter 2
- Rosenbaum Causal Inference Chapters 1-3

Class 3 Recording 2024-02-01 9 AM to 11 AM

- We'll walk through direct adjustment for the PS and 1:1 matching with the PS. (No R code in slides)
- Class 4 Recording: Essentially nothing but R code.
- Skim Connors 1996 and Gum 2001 to see how propensity score matching has been done in practice.